Incidence and Risk Factors of Venous and Arterial Thromboembolism in Immune Checkpoint Inhibitor Therapy

Curr Pharm Des. 2022;28(36):2950-2952. doi: 10.2174/1381612828666220919123712.

Authors

Tingting Liu¹, Liang V Tang¹

Affiliation

¹ School of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.

PMID: 36121074
DOI: 10.2174/1381612828666220919123712

No abstract available

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Incidence
Retrospective Studies
Risk Factors
Venous Thromboembolism* / drug therapy
Venous Thromboembolism* / epidemiology

Substances

Immune Checkpoint Inhibitors